MedTrace Logo

A Study for Participants With Small-Cell Lung Cancer

NCT01025284 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-09-17

Study results available
· View outcomes & findings →

Summary

Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.

Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.

Conditions

Interventions

DRUG

LY2523355

Administered intravenously as a 1-hour infusion

DRUG

Granulocyte colony-stimulating factor (G-CSF)

Administered subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time(UTC/GMT-5hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States
  • Romania
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025284 on ClinicalTrials.gov